Novel Regulation of Receptor Tyrosine Kinases by ASM (Acidic Sphingomyelinase)

ASM(酸性鞘磷脂酶)对受体酪氨酸激酶的新调控

基本信息

  • 批准号:
    9232921
  • 负责人:
  • 金额:
    $ 42.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-15 至 2020-05-30
  • 项目状态:
    已结题

项目摘要

Project Summary We propose that ASM (acid sphingomylinase) is a critical regulator of RTKs (receptor tyrosine kinases), and that ASM can serve as a novel therapeutic target for various cancers, including gliomablastoma multiforme (GBM). Also as loss of function of ASM may cause the severe neuron degeneration phenotype in the rare familial Niemann Pick Disease, type A, our studies may provide molecular insights into this disease. The plasma membrane is a lipid bilayer composed primarily of phospholipids, as well as sphingomyelins, cholesterol, glycosphingolipids and other less abundant lipid molecules such as ceremides. The composition of the plasma membrane lipids is dynamically regulated and undergoes rapid exchanges with intracellular organelles such as Golgi, endosomes and lysosomes through secretion, exocytosis and endocytosis. For many transmembrane and membrane-associated proteins, including RTKs, specific interaction with various lipid molecules in the plasma membrane is an integral part of regulation to maintain their protein structure and function. However, the mechanisms by which specific lipid molecules regulate the dynamic activities of RTKs and other transmembrane or membrane-associated proteins are not well characterized. In this application, we propose to investigate the roles of ASM (also called SMPD1) in regulating the RTK-mediated cell signaling processes. We have recently found that the levels of ASM (acidic sphinomyelinase) are highly elevated in GBM and our studies reveal that ASM is required for the activation of multiple RTKs. ASM is an enzyme involved in sphingolipid metabolism that hydrolyzes sphingomyelin to produce ceramide. Ceramide, with a biophysical property of self-association, is involved in establishing a lipid microenvironment that promotes protein-protein interactions. Mutations of human ASM gene cause Niemman-Pick disease, type A, an inherited disease that induces massive loss of Purkinje neurons in the cerebellum and patients usually die by 2 or 3 years of ages, but the underlying molecular mechanism of ASM deficiency for the disease remains unresolved. In this application, we will investigate the mechanism by which ASM regulates the RTK signaling pathway, by following specific aims: Specific aim 1: To determine how ASM regulates the activation RTK receptor proteins. Specific aim 2: To investigate the involvement of ASM sphinomyelinase activity in RTK signaling. Specific aim 3: To examine whether ASM regulates RTK signaling at multiple levels. As co-activation of RTKs is critically important in GBM and in a multitude of human disorders and diseases, elucidation of this new regulatory mechanism may provide novel targets for prevention and therapeutic treatment. Our studies should also provide molecular underpinning how loss-of-function of ASM causes neuron degeneration in the human diseases such as Niemman-Pick disease, type A.
项目摘要 我们认为ASM(酸性鞘磷脂酶)是RTK(受体酪氨酸激酶)的关键调节因子, ASM可以作为多种癌症新的治疗靶点,包括多形性胶质母细胞瘤 (GBM)。此外,由于ASM功能丧失可能导致罕见的神经元变性表型, 家族性尼曼匹克病,A型,我们的研究可能会提供这种疾病的分子见解。 质膜是主要由磷脂以及鞘磷脂组成的脂质双层, 胆固醇、鞘糖脂和其它不太丰富的脂质分子如蜡酰亚胺。的组合物 质膜脂质是动态调节的,并与细胞内的脂质进行快速交换, 细胞器如高尔基体、内体和溶酶体通过分泌、胞吐和胞吞作用。对于许多 跨膜和膜相关蛋白,包括RTK,与各种脂质的特异性相互作用 质膜中的分子是维持其蛋白质结构的调节的组成部分, 功能然而,特定脂质分子调节RTK动态活性的机制 而其它跨膜或膜相关蛋白没有得到很好的表征。在本申请中,我们 本文拟研究ASM(也称为SMPD 1)在调控RTK介导的细胞信号转导中的作用 流程. 我们最近发现,ASM(酸性鞘磷脂酶)的水平在GBM中高度升高, 研究表明,ASM是激活多种RTK所必需的。ASM是一种酶, 水解鞘磷脂产生神经酰胺的鞘脂代谢。神经酰胺,具有生物物理 自缔合的性质,参与建立脂质微环境,促进蛋白质-蛋白质 交互.人类ASM基因突变导致A型尼曼-皮克病,这是一种遗传性疾病, 引起小脑浦肯野神经元的大量损失,患者通常在2或3岁时死亡, ASM缺陷导致该疾病的潜在分子机制仍未解决。 在本申请中,我们将研究ASM调节RTK信号通路的机制, 具体目标如下: 具体目标1:确定ASM如何调节RTK受体蛋白的活化。 具体目标2:研究ASM鞘磷脂酶活性在RTK信号传导中的参与。 具体目标3:检查ASM是否在多个水平上调节RTK信号传导。 由于RTK的共激活在GBM和许多人类病症和疾病中至关重要, 阐明这种新的调节机制可能为预防和治疗提供新的靶点。 治疗我们的研究还应该提供ASM功能丧失如何导致神经元损伤的分子基础。 在人类疾病如A型尼曼-皮克病中的变性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HONG SUN其他文献

HONG SUN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HONG SUN', 18)}}的其他基金

Novel Regulation of the Activation and Assembly of the Heterimeric Receptor Tyrosine Kinase Complexes for Cell Signaling
细胞信号转导异聚受体酪氨酸激酶复合物的激活和组装的新调控
  • 批准号:
    10046499
  • 财政年份:
    2016
  • 资助金额:
    $ 42.8万
  • 项目类别:
PTEN TUMOR SUPPRESSOR AND CELL CYCLE REGULATION
PTEN 肿瘤抑制剂和细胞周期调节
  • 批准号:
    6513335
  • 财政年份:
    1999
  • 资助金额:
    $ 42.8万
  • 项目类别:
PTEN TUMOR SUPPRESSOR AND CELL CYCLE REGULATION
PTEN 肿瘤抑制剂和细胞周期调节
  • 批准号:
    6633295
  • 财政年份:
    1999
  • 资助金额:
    $ 42.8万
  • 项目类别:
PTEN TUMOR SUPPRESSOR AND CELL CYCLE REGULATION
PTEN 肿瘤抑制剂和细胞周期调节
  • 批准号:
    6376738
  • 财政年份:
    1999
  • 资助金额:
    $ 42.8万
  • 项目类别:
PTEN TUMOR SUPPRESSOR AND CELL CYCLE REGULATION
PTEN 肿瘤抑制剂和细胞周期调节
  • 批准号:
    2909850
  • 财政年份:
    1999
  • 资助金额:
    $ 42.8万
  • 项目类别:
PTEN TUMOR SUPPRESSOR AND CELL CYCLE REGULATION
PTEN 肿瘤抑制剂和细胞周期调节
  • 批准号:
    6173631
  • 财政年份:
    1999
  • 资助金额:
    $ 42.8万
  • 项目类别:

相似海外基金

Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
  • 批准号:
    24K21101
  • 财政年份:
    2024
  • 资助金额:
    $ 42.8万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
  • 批准号:
    24K11201
  • 财政年份:
    2024
  • 资助金额:
    $ 42.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
  • 批准号:
    24K11281
  • 财政年份:
    2024
  • 资助金额:
    $ 42.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
  • 批准号:
    EP/Z001145/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.8万
  • 项目类别:
    Fellowship
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
  • 批准号:
    2338890
  • 财政年份:
    2024
  • 资助金额:
    $ 42.8万
  • 项目类别:
    Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334777
  • 财政年份:
    2024
  • 资助金额:
    $ 42.8万
  • 项目类别:
    Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334775
  • 财政年份:
    2024
  • 资助金额:
    $ 42.8万
  • 项目类别:
    Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334776
  • 财政年份:
    2024
  • 资助金额:
    $ 42.8万
  • 项目类别:
    Continuing Grant
Cryo laser-ablation system (157+193nm) with 'triple-quad' plasma mass spectrometer, Cryo-LA-ICPMS/MS
带有“三重四极杆”等离子体质谱仪、Cryo-LA-ICPMS/MS 的冷冻激光烧蚀系统 (157 193nm)
  • 批准号:
    515081333
  • 财政年份:
    2023
  • 资助金额:
    $ 42.8万
  • 项目类别:
    Major Research Instrumentation
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
  • 批准号:
    2320040
  • 财政年份:
    2023
  • 资助金额:
    $ 42.8万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了